| Jan'20 | Jan'19 | Jan'18 | ||||
|---|---|---|---|---|---|---|
Revenue: | ||||||
Revenues | ||||||
124,784 | 99,889 | 79,834 | ||||
Expenses: | ||||||
Cost of revenue (excluding depreciation and amortization) | ||||||
16,831 | 15,105 | 12,562 | ||||
Payment processing expense | ||||||
27,889 | 21,892 | 17,209 | ||||
Sales and marketing | ||||||
32,357 | 26,367 | 24,761 | ||||
Research and development | ||||||
18,623 | 14,349 | 11,377 | ||||
General and administrative | ||||||
30,458 | 20,076 | 18,838 | ||||
Depreciation | ||||||
8,753 | 7,552 | 6,832 | ||||
Amortization | ||||||
5,171 | 4,042 | 2,808 | ||||
Total expenses | ||||||
140,082 | 109,382 | 94,387 | ||||
Operating loss | ||||||
-15,298 | -9,494 | -14,553 | ||||
Other income (expense) | ||||||
-1,023 | -7 | 602 | ||||
Change in fair value of warrant liability | ||||||
3,307 | 2,058 | 598 | ||||
Interest income (expense) | ||||||
-2,445 | -3,504 | -3,642 | ||||
Total other income (expense) | ||||||
-6,775 | -5,568 | -3,639 | ||||
Loss before benefit from (provision for) income taxes | ||||||
-22,073 | -15,062 | -18,192 | ||||
Benefit from (provision for) income taxes | ||||||
-1,780 | 0 | 0 | ||||
Net loss | ||||||
-20,293 | -15,062 | -18,192 | ||||
Preferred stock dividends paid | ||||||
14,955 | 0 | 0 | ||||
Accretion of redeemable preferred stock | ||||||
56,175 | 30,199 | 19,981 | ||||
Net loss attributable to common stockholders | ||||||
-91,423 | -45,261 | -38,173 | ||||
Net loss per share attributable to common stockholders, basic and diluted (in usd per share) | ||||||
-4.50 | -24.53 | -24.81 | ||||
Weighted-average common shares outstanding, basic and diluted (in shares) | ||||||
20,301 | 1,844 | 1,538 | ||||
Payment processing fees | ||||||
Revenues from contract with customer | ||||||
46,500 | 36,881 | 28,671 | ||||
Life sciences | ||||||
Revenues from contract with customer | ||||||
21,927 | 19,080 | 18,733 | ||||
Subscription and related services | ||||||
Revenues | ||||||
56,357 | 43,928 | 32,430 | ||||